ライフサイエンスコーパス: adverse events

1 cceptability of the intervention was high and there were no adverse events.

2 ration of abnormal peak flow, antibiotic use, or nonserious adverse events.

3 ociated with increased risk of complicated appendicitis and adverse events.

4 The main safety measure was adverse events.

5 ive cohort, the primary outcomes were treatment failure and adverse events 14 days after diagnosis.

6 Safety measures included adverse events (AEs), clinical laboratory tests, vital signs,

7 The primary outcome was the incidence of adverse events among vaccine and placebo recipients throughou

8 urces of referral, body region scanned, type, dose, related adverse events and route of administration of sedatives as we

9 Treatment-related adverse events (any grade) prompted treatment discontinuation

10 17 (5%) of 370 patients died from non-treatment-related adverse events associated with death, and one patient died fr

11 However, the adverse events associated with smoking limit its clinical sig

12 26 (39%) of 44 patients had grade 3 adverse events, but no grade 4 events were reported.

13 eceiving an AI; secondary objectives included evaluation of adverse events, changes in sexual quality of life using the C

14 The overall rate of serious adverse events did not differ between treatment groups, altho

15 There were no adverse events either immediately or at 2-week follow-up.

16 Nine patients died from adverse events; five of these deaths were judged to be relate

17 12 patients reported serious adverse events; haemolysis and pyrexia were the most common (

18 ent of clinical outcome mainly relies on the declaration of adverse events, identification of their predictors, self-asse

19 We recorded adverse events in ten (34%) of 29 patients given twice-weekly

20 oor practice, and recognising, responding to and disclosing adverse events, including errors and near misses.

21 Frequency of adverse events, mostly mild self-limited joint and back pain,

22 ted with death, and one patient died from treatment-related adverse events (myositis in addition to grade 3 thyroiditis,

23 Two (1%) of 166 patients had serious adverse events; neither were considered related to study drug

24 d placebo groups, and only grade 1 (mild) local or systemic adverse events occurred in both groups.

25 not differ between treatment groups, although some specific adverse events occurred more often in the intensive group.

26 Serious adverse events occurring in more than two patients included a

27 The most common adverse events of grade 3 or higher during treatment were neu

28 The most common adverse events of grade 3 or worse severity were anaemia (38

29 We detected no significant differences in local or systemic adverse events or laboratory abnormalities between the PfSPZ

30 unless disease recurrence or new breast cancer, intolerable adverse events, or consent withdrawal occurred.

31 Rate of adverse events, quality of life, and patient satisfaction wer

32 SMX (29 of 261 [11.1%]) or placebo (32 of 255 [12.5%]); all adverse events resolved without sequelae.

33 The most common serious adverse events that occurred through week 24 were anaemia (10

34 bases were searched for studies in which rates of immediate adverse events to GBCAs were reported.

35 7) PFU dose (used in phase 3 trials), the most common local adverse events versus placebo within the first 14 days were a

36 roportion of patients who discontinued treatment because of adverse events was low (range, 0%-1%).

37 Incidence of adverse events was similar for alirocumab versus control, exc

38 Incidence of adverse events was similar in all groups (43 [88%] of 49 in t

39 The number of adverse events was similar regardless of immunisation status.

40 The most common serious adverse events were anaemia (eight [4%]), upper gastrointesti

41 Serious adverse events were experienced by 35 (18%) patients in the o

42 Treatment-related adverse events were generally grade 1 or 2 in severity.

43 The most common adverse events were infective pulmonary exacerbations, cough,

44 The most common isatuximab-related adverse events were infusion-associated reactions (IARs) (56%

45 Data on adverse events were limited, but suggested an increased risk

46 Fewer grade 3 and 4 treatment-related adverse events were observed in patients on nivolumab (14% v

47 No severe adverse events were recorded.

48 Serious adverse events were reported in 56 (58%) eltrombopag-treated

49 The most frequently observed grade 3 and 4 adverse events were transaminase increases (40% alanine amino

50 Safety was assessed on the basis of adverse events, which were graded according to the Common Ter